MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis
- PMID: 18806155
- DOI: 10.2214/AJR.08.1038.1
MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis
Abstract
Objective: This article is the first part of a two-part series on MRI safety. In this article, part 1, the topic of MRI contrast agents and nephrogenic systemic fibrosis (NSF) is addressed.
Conclusion: To prevent incidents and accidents associated with MRI, it is necessary to regularly revisit the safety topics that directly impact patient management especially with respect to the subjects that are "new" (e.g., MRI contrast agents and NSF), those that should be reassessed because of recent changes, topics that deserve emphasis because of controversy or confusion, and information that should be considered in light of new findings.
Comment in
-
Nephrogenic systemic fibrosis and gadolinium: a perfect storm.AJR Am J Roentgenol. 2008 Oct;191(4):1150-3. doi: 10.2214/AJR.08.1327. AJR Am J Roentgenol. 2008. PMID: 18806157 No abstract available.
-
Gadolinium and nephrogenic systemic fibrosis.AJR Am J Roentgenol. 2009 Apr;192(4):W195-6; discussion W197. doi: 10.2214/AJR.08.1949. AJR Am J Roentgenol. 2009. PMID: 19304681 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
